Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Analysis of the clinical antibacterial and antituberculosis pipeline

Open access
Theuretzbacher, Ursula, Gottwalt, Simon, Beyer, Peter, Butler, Mark, Czaplewski, Lloyd, Lienhardt, Christian, Moja, Lorenzo, Paul, Mical, Paulin, Sarah, Rex, John H, Silver, Lynn L, Spigelman, Melvin, Thwaites, Guy E, Paccaud, Jean-Pierre, Harbarth, Stephan·2019·The Lancet Infectious Diseases

Abstract

This analysis of the global clinical antibacterial pipeline was done in support of the Global Action Plan on Antimicrobial Resistance. The study analysed to what extent antibacterial and antimycobacterial drugs for systemic human use as well as oral non-systemic antibacterial drugs for Clostridium difficile infections were active against pathogens included in the WHO priority pathogen list and their innovativeness measured by their absence of cross-resistance (new class, target, mode of action). As of July 1, 2018, 30 new chemical entity (NCE) antibacterial drugs, ten biologics, ten NCEs against Mycobacterium tuberculosis, and four NCEs against C difficile were identified. Of the 30 NCEs, 11 are expected to have some activity against at least one critical priority pathogen expressing carbapenem resistance. The clinical pipeline is dominated by derivatives of established classes and most development candidates display limited innovation. New antibacterial drugs without pre-existing cross-resistance are under-represented and are urgently needed, especially for geographical regions with high resistance rates among Gram-negative bacteria and M tuberculosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(18)30513-9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 220

Metadata

Authors
Theuretzbacher, U., Gottwalt, S., Beyer, P., Butler, M., Czaplewski, L., Lienhardt, C., Moja, L., Paul, M., Paulin, S., Rex, J. H., Silver, L. L., Spigelman, M., Thwaites, G. E., Paccaud, J.-P., & Harbarth, S.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2019-02
Volume
19
Issue
2
Pages
e40-e50
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2896832238
Cited by
220
References
2
FWCI
8.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of the clinical antibacterial and antituberculosis pipeline. https://app.cochat.ai/papers/10.1016/s1473-3099(18)30513-9
The paper
Theuretzbacher, U., Gottwalt, S., Beyer, P., Butler, M., Czaplewski, L., Lienhardt, C., Moja, L., Paul, M., Paulin, S., Rex, J. H., Silver, L. L., Spigelman, M., Thwaites, G. E., Paccaud, J.-P., & Harbarth, S. (2019). Analysis of the clinical antibacterial and antituberculosis pipeline. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(18)30513-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.